AGENUS INC (AGEN) Stock Price, Quote, News and Overview
NASDAQ:AGEN - Nasdaq - US00847G8042 - Common Stock - Currency: USD
AGEN Quote, Performance and Key Statistics
2.87
+0.56 (+24.24%)
The current stock price of AGEN is 2.87 USD. In the past month the price increased by 75%. In the past year, price decreased by -75.45%.
AGEN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.17 | 307.41B | ||
| AMGN | AMGEN INC | 14.05 | 149.68B | ||
| GILD | GILEAD SCIENCES INC | 22.89 | 131.53B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1691.28 | 126.09B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.83 | 64.01B | ||
| ARGX | ARGENX SE - ADR | 322.51 | 36.63B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.80B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.24B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.16B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.17B | ||
| NTRA | NATERA INC | N/A | 19.55B | ||
| BIIB | BIOGEN INC | 7.22 | 17.40B |
Related stock screener links
About AGEN
Company Profile
Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 389 full-time employees. The company went IPO on 2000-02-04. The company is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Company Info
AGENUS INC
3 Forbes Rd
Lexington MASSACHUSETTS 02421 US
CEO: Garo H. Armen
Employees: 389
Company Website: https://agenusbio.com/
Investor Relations: https://investor.agenusbio.com/
Phone: 17816744400
AGENUS INC / AGEN FAQ
What is the stock price of AGENUS INC today?
The current stock price of AGEN is 2.87 USD. The price increased by 24.24% in the last trading session.
What is the ticker symbol for AGENUS INC stock?
The exchange symbol of AGENUS INC is AGEN and it is listed on the Nasdaq exchange.
On which exchange is AGEN stock listed?
AGEN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AGENUS INC stock?
11 analysts have analysed AGEN and the average price target is 7.14 USD. This implies a price increase of 148.78% is expected in the next year compared to the current price of 2.87. Check the AGENUS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AGENUS INC worth?
AGENUS INC (AGEN) has a market capitalization of 72.64M USD. This makes AGEN a Micro Cap stock.
How many employees does AGENUS INC have?
AGENUS INC (AGEN) currently has 389 employees.
What are the support and resistance levels for AGENUS INC (AGEN) stock?
AGENUS INC (AGEN) has a resistance level at 2.96. Check the full technical report for a detailed analysis of AGEN support and resistance levels.
Is AGENUS INC (AGEN) expected to grow?
The Revenue of AGENUS INC (AGEN) is expected to decline by -0.85% in the next year. Check the estimates tab for more information on the AGEN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AGENUS INC (AGEN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AGEN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AGEN, evaluating the profitability, health, valuation and growth aspects
- AGENUS INC (AGEN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AGENUS INC (AGEN) Sales and EPS estimates to see what analysts future expectations are.
- AGENUS INC (AGEN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AGENUS INC (AGEN) Insider and Institutional Ownership to learn about the owners and their transactions.
- AGENUS INC (AGEN) Stock Chart to make your own analysis
- AGENUS INC (AGEN) Latest news and press-releases to stay up to date.
Does AGENUS INC (AGEN) stock pay dividends?
AGEN does not pay a dividend.
When does AGENUS INC (AGEN) report earnings?
AGENUS INC (AGEN) will report earnings on 2025-05-05, before the market open.
What is the Price/Earnings (PE) ratio of AGENUS INC (AGEN)?
AGENUS INC (AGEN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-10.68).
What is the Short Interest ratio of AGENUS INC (AGEN) stock?
The outstanding short interest for AGENUS INC (AGEN) is 13.94% of its float. Check the ownership tab for more information on the AGEN short interest.
AGEN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to AGEN. When comparing the yearly performance of all stocks, AGEN is a bad performer in the overall market: 91.23% of all stocks are doing better.
AGEN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AGEN. AGEN may be in some trouble as it scores bad on both profitability and health.
AGEN Financial Highlights
Over the last trailing twelve months AGEN reported a non-GAAP Earnings per Share(EPS) of -10.68. The EPS increased by 24.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -100.51% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AGEN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 75% to AGEN. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 61.51% and a revenue growth -0.85% for AGEN